Best alternative to vancomycin for serious methicillin-resistant staphylococcus aureus infections: Let's just say it

Clinical Infectious Diseases

Volumn 53, Issue 9, 2011, Pages 965-966

  Bush, Larry M ^a,b,c  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JFK Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; PENICILLIN G; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HEALTH CARE COST; HUMAN; LENGTH OF STAY; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 80054064391     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir528     Document Type: Letter

References (10)

1. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise T. Vancomycin: We can't get there from here. Clin Infect Dis 2011; 52:969-74.
2. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81.
3. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high vancomycin minimum inhibitory concentration in methicillinresistant Staphylococcus aureus bloodstream infections. Clin Infect Dis 2011; 52:997-1002.
4. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275-9.
5. Liu C, Bayer A, Cosgrove SE, et al. Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-e55.
6. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81. (Pubitemid 38781657)
7. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcal aureus bacteremia. Arch Int Med 2003; 163:2066-72. (Pubitemid 37151249)
8. Fowler VG Jr, Boucher HW, Corey GR, et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
9. Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG. Cost-effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infec Dis 2009; 49:691-8.
10. Bush LM, Boscia JA, Wendeler M, Pitsakis PG, Kaye D. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1989; 33:1198-200. (Pubitemid 19191956)